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ABSTRACT 
Neglected tropical diseases (NTDs) are a group of 17 infectious diseases with a wide range of 
symptoms and findings, affecting more than one billion people worldwide, mostly the poor. 
Over the past few years, the World Health Organization (WHO) and partners have committed 
to strengthening the fight against the NTDs by setting specific goals for control, elimination 
and eradication of the respective diseases. Mass drug administration (MDA) is an important 
strategy in the fight against several of the NTDs; however, in order to meet the WHO targets 
by 2020, high and sustained treatment coverage will be essential. Social sciences, a previously 
neglected aspect of NTD control programmes, could help strengthen and further develop 
MDA and the promotion of healthy behaviour. Lessons learned from other disease control 
programmes, such as the recent Ebola epidemic, could lend inspiration to the further fight 
against NTDs. In this review, we found only a limited number of primarily observational 
studies of social scientific approaches to the control of NTDs. There is a need for creative, yet 
robust studies to address the challenges of quantitatively measuring the effect of social 
sciences in a meaningful way. Qualitative studies of other global health challenges indicate 
that social sciences do have an important role to play, and medical, public health and social 
scientists will need to find ways of working together in order to successfully combat NTDs. 
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INTRODUCTION 
The term ‘neglected tropical diseases’ (NTDs) includes a group of 17 infectious diseases 
caused by protozoa (American trypanosomiasis (Chagas disease), human African 
trypanosomiasis, leishmaniasis), helminths (cysticercosis/taeniasis, dracunculiasis, 
echinococcosis, foodborne trematodiases, lymphatic filariasis, onchocerciasis, 
schistosomiasis, soil-transmitted helminthiases), bacteria (Buruli ulcer, leprosy, trachoma, 
yaws) and viruses (dengue, rabies) [1]. Their disease presentation includes a wide range of 
symptoms and findings, and may affect multiple organ systems (Table 1). 
 
NTDs affect more than one billion people worldwide and are responsible for a substantial 
global burden of disease, causing more than 26 million Disability-Adjusted Life Years 
(DALYs) annually [2, 3]. The impact of NTDs on individuals, families and communities in 
developing countries cause not only a huge burden of disease, but also impacts the quality of 
life and productivity. The diseases affect populations with low political visibility and voice, 
whose influence on decision and policy-making is minimal. The disfigurement and disability 
caused by NTDs particularly affects girls and women [4], contributing to gender-based 
inequality.  
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Disease Main causative agents Organs affected 
Prevalenc
e 
1,000 
DALYs 
(2010)* 
Ref 
American 
trypanosomiasis 
Trypanosoma cruzi 
Intracellular, 
systemic 
7 million 
546 (271–
1,054) 
[1, 3, 
5] 
Human African 
trypanosomiasis 
Trypanosoma brucei 
Blood, lymphatics, 
cerebrospinal fluid 
6,314 
560 (76–
1,766) 
[1, 3, 
6] 
Leishmaniasis 
More than 20 species of 
Leishmania 
CL: skin  
VL: systemic 
1.3 million 
3,317 
(2,180–
4,890) 
[1, 3, 
6] 
Cysticercosis/ 
Taeniasis 
Taenia solium 
Muscle, skin, CNS, 
eyes 
No data 
503 (379–
663) 
[1, 3] 
Dracunculiasis Dracunculus medinensis 
Large intestines, 
especially caecum 
126 
No data 
found 
[6, 7] 
Echinococcosis 
Echinococcosis granulosus 
Echinococcosis multilocularis 
Liver, lungs, CNS, 
bones, kidneys, 
spleen, muscles, 
retro-ocular space 
30/100 000 
person-
years in 
endemic 
areas 
144 (69–
286) 
[1, 3] 
Foodborne 
trematodiases 
Clonorchis sinensis, 
Opisthorchis felineus, 
Opisthorchis viverrini,  
Fasciola hepatica  
Echinostoma spp 
Fasciolopsis buski 
Paragonimus spp  
Liver, lungs, 
intestines 
56 million 
665 (479-
859) 
[1, 3, 
8] 
Lymphatic 
filariasis 
Wuchereria bancrofti  
Brugia malayi 
Brugia timori 
Lymphatics 
120 
million 
2,775 
(1,807–
4,000) 
[1, 3, 
6] 
Onchocerciasis Onchocerca volvulus 
Subcutaneous 
tissues 
37 million 
494 (360–
656) 
[1, 3, 
6] 
Schistosomiasis 
Schistosoma manson  
S. haematobium 
S. japonicum 
Urogenital tract, 
intestines, ectopic 
249 
million 
3,309 
(1,705–
6,260) 
[1, 3, 
6] 
Soil-transmitted 
helminthiases 
Ascaris lumbricoides  
Trichuris trichiura 
Necator americanus 
Ancylostoma duodenale 
Lungs, intestines 1.7 billion 
5,190 
(2,980-
8,810) 
[1, 2, 
9] 
Buruli ulcer Mycobacterium ulcerans Skin 5,000 
No data 
found 
[1, 6] 
Leprosy Mycobacterium leprae Skin and nerves 215,656 6 (3–11) 
[1, 3, 
6] 
Trachoma Chlamydia trachomatis Conjunctiva 21 million 
334 (243–
438) 
[1, 3, 
6] 
Yaws T. pallidum pertenue Skin 
Approx.  
60,000 
No data 
found 
[1, 
10] 
Dengue 
Aedes aegypti  
Ae. albopictus 
Systemic 
390 
million 
825 (344–
1,412) 
[1, 3, 
11] 
Rabies Rabies virus CNS Not known 
1,462 
(852–
2,659) 
[1, 3] 
Table 1: Symptoms and findings of 17 neglected tropical diseases. 
*In parentheses the 95% confidence interval, CL = cutaneous leishmaniasis, VL: visceral 
leishmaniasis, CNS = central nervous system 
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Despite the substantial disease burden, NTDs receive relatively limited attention from the 
international community, and thereby inadequate funding for research, including studies of 
diagnostic tools and novel treatment methods, compared to other comparable diseases such as 
human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), 
malaria and tuberculosis [12]. Still, the treatment of most NTDs is safe and relatively simple 
to administer, and treatment of multiple co-infections may be integrated [13]. Since 2007, the 
World Health Organization (WHO) has committed to strengthen the fight against NTDs, and 
a number of stakeholders worldwide have joined the partnership. 
 
In 2012, a coalition of endemic country governments, pharmaceutical companies, and non-
governmental organisations (NGOs) came together to commit to the fight against NTDs, in 
what has been named the London declaration on NTDs [14]. A WHO and partners roadmap 
was developed for targeted control and elimination of NTDs [15]. Here, we review the present 
global health strategies to fight these diseases, and the status of control and elimination targets 
set by WHO. We thereafter explore and discuss some of the gaps that need to be filled in 
order to achieve the goals set for 2020, in particular alternative approaches that include the 
integration of social sciences in the combat of NTDs. 
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PROGRESS OF CONTROL AND ELIMINATION 
Ten NTDs are targeted for control, elimination or eradication by WHO and partners, and 
below we review them in order of burden of global DALYs [2].  
 
Soil-transmitted helminthiases (STHs) are caused by a group of helminths including 
Necator americanus and Ancylostoma duodenale (hookworms), Ascaris lumbricoides 
(roundworm) and Trichuris trichiura (whipworm). STHs commonly lead to undernutrition 
and anaemia, stunted growth and may prevent cognitive development, although this can be 
difficult to detect for all STHs collectively at the community level [16]. The STHs are 
targeted for global control1 by 2020 [1]. Up to 2 billion people are at risk of STHs worldwide, 
and 876 million of them are children [9]. Mass drug administration (MDA) of pre-school and 
school-age children with albendazole or mebendazole is currently the key strategy to fight 
these infections; however, studies indicate that also adults should be treated in order to 
adequately control these diseases [17]. The treatment coverage target for 2020 is at least 75% 
of pre-school and school-age children in endemic countries; however, in 2013, only about 50 
and 40 % of at-risk preschool-age and school-age children, respectively, were treated 
worldwide [18]. Currently, only 27% of countries have reached these targets, and, alongside 
MDA, interventions to improve access to safe drinking water and improved sanitation, as well 
as health education for improved hygiene in at-risk populations, will be needed [19].  
 
Visceral leishmaniasis is a disease transmitted through bites of infected sand-flies. The 
parasite, Leishmania, attacks the immune system, bone marrow and internal organs, such as 
the liver and spleen, and, if left untreated, is usually fatal within few years [20]. WHO has set 
                                                     
1 Control is defined by WHO as: ”The reduction of disease incidence, prevalence, intensity, 
morbidity, or mortality, or a combination of these, as a result of deliberate efforts. (…) 
Continued intervention measures may be required to maintain this reduction.”  
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the target to eliminate2 visceral leishmaniasis as a public health problem by 2020, and to 
significantly reduce associated morbidity and mortality in other endemic regions [1]. 
Approximately 300,000 new cases are detected annually, and Bangladesh, Brazil, Ethiopia, 
India, Nepal, South Sudan and Sudan account for 90% of those. Up to 50,000 deaths occur 
every year due to infection, and strategies to achieve elimination include early diagnosis and 
treatment with a single intravenous dose of liposomal amphotericin B, a drug which is 
thought to disrupt the parasitic membrane through drug-binding to parasite [21]. Other efforts 
include transmission interruption through the use of insecticides and community education to 
change risk behaviour [22]. From 2012 to 2013, the number of reported cases in the three 
highest-burden countries, Bangladesh, India, and Nepal, was reduced by 37%, 33% and 50%, 
respectively [1].  
 
Schistosomiasis is caused by mainly three species of the parasitic worm Schistosoma, of 
which S. haematobium and S. mansoni are the two predominant species [23]. People are 
infected through contact with infested fresh water, contaminated with larvae from the 
intermediate snail hosts, and symptoms include abdominal pain, diarrhoea, bloody stools, 
haematuria, and genital symptoms such as haematospermia, cervicitis and sterility. The 
disease may lead to liver and kidney damage, and in long-standing cases, gastroesophageal 
varices or urinary bladder cancer [24]. Schistosomiasis is targeted for global control by 2020, 
and WHO urges endemic countries to treat at least 75% of all school-age children and at-risk 
adults in need of treatment through preventive chemotherapy with praziquantel [1]. However, 
in 2012, only 14% of the people in need of treatment received praziquantel worldwide [1], 
although unprecedented donations by pharmaceutical companies have provided enough 
                                                     
2 Elimination is defined by WHO as: ”The reduction to zero of the incidence (…) in a defined 
geographical area (…); continued actions to prevent re-etablishment of transmission may be 
required.” 
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praziquantel to treat all school-age children in need of treatment worldwide. Drug availability 
alone is therefore not enough to ensure that WHO coverage targets are reached [25]. 
 
Lymphatic filariasis (LF) is caused by mosquito-transmitted helminths that invade and 
damage the lymphatic system, causing disfiguring thickening of the skin and swelling 
(lymphedema) of the lower extremities (elephantiasis), scrotum (hydrocele) and female 
breasts [26]. The disease is targeted for global elimination by 2020 [1]. In 2013, at least 40 
million people had clinical manifestations, whereas 1.4 billion people worldwide required 
preventive chemotherapy for LF. MDA is the core strategy to eliminate the disease, and a 
combination of albendazole and diethylcarbamazine (DEC) or ivermectin is used to break the 
transmission cycle through annual MDA [27]. Following five years of MDA, surveillance 
systems are put in place to verify the absence of disease transmission [1]. In 2013, over 400 
million people worldwide were treated for LF [13]; however, in all African countries 
combined, the coverage was only 32% [28].  
 
Human African trypanosomiasis is transmitted by infected Tsetse flies, and is mostly found 
in sub-Saharan Africa. Two types of protozoa cause chronic disease (Trypanosoma brucei 
gambiense, accounts for 98% of cases) and acute disease (T. brucei rhodesiense), 
respectively. Acute symptoms include fever and joint pain, and the parasite may invade the 
central nervous system, causing behavioural changes, confusion, sensory and sleep 
disturbances, giving the disease its more common name “sleeping sickness” [29]. The disease 
is targeted for global elimination by 2020 [1], and the number of infected individuals has 
gradually declined, with only 3,796 reported new cases in 2014, down 40% from 2013 [30]. 
Through the development and implementation of rapid diagnostic tests and more effective and 
simpler drugs, the target is fewer than 2,000 cases in 2020 [31]. 
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American trypanosomiasis, or Chagas disease, is mostly found in rural Latin America. The 
disease is caused by the protozoa T. cruzi, and is transmitted through food, blood transfusions, 
and organ donations, and peripartum. The infection may lead to complications such as 
cardiomyopathy, megacolon and mega-oesophagus [32]. Chagas disease is targeted for global 
control by 2020 [1]. Around 6 million people are thought to be infected, and public health 
control strategies include organ and blood donation screening through the use of rapid 
diagnostic tests, and early anti-parasitic treatment of infected individuals [22]. In addition to 
these screening measures, elimination of disease-carrying insects in areas surrounding homes 
in Latin America are targeted for elimination by 2020 [33]. 
 
Onchocerciasis, also known as river blindness, is caused by the parasitic worm Onchocerca 
volvulus transmitted by blackflies. The flies breed in fast-flowing rivers, and in humans 
inflammation caused by the death of the parasite larvae leads to damage of the skin and eyes 
(cornea), resulting in severe skin itching and potentially blindness [34]. Onchocerciasis is 
targeted for elimination by 2015 in Latin America and Yemen, and by 2020 in selected 
countries in Africa [15, 16]. It is the world’s second leading infectious cause of blindness, 
after trachoma, and an estimated 37 million people in sub-Saharan Africa are infected, 
representing 99% of the global burden of this disease [1]. MDA of ivermectin is used to 
interrupt transmission, and, since 1995, individuals in affected communities in Africa have 
been trained to distribute ivermectin to fellow community members through so-called 
community-directed treatment supplied through the African Programme for Onchocerciasis 
Control (APOC). In 2013, more than 100 million people were treated for onchocerciasis, and 
12 African countries are expected to achieve elimination by 2020 [1]. In 2015, APOC 
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formally came to an end, and the challenge remains to sustain the high treatment coverage, 
such as through integration with other NTD control and elimination programmes [28]. 
 
Trachoma is caused by infection with the bacteria Chlamydia trachomatis, and is the most 
common cause of preventable blindness worldwide. The disease is targeted for global 
elimination by 2020 [1]. The so-called SAFE strategy has been put in place to ensure 
adequate measures of prevention and treatment are provided to at-risk populations: Surgery of 
trachomatous trichiasis3, Antibiotics (oral azithromycin) to treat on-going bacterial infections, 
Facial cleanliness to reduce transmission of disease, and Environmental improvements, such 
as access to safe water and sanitation facilities [35]. In 2015, more than 21 million people are 
estimated to have active trachoma and more than 230 million are at risk of infection [1]. In 
2014, the WHO Alliance for the global elimination of trachoma by 2020 concluded that 
increased efforts are needed to ensure the F and E aspects of the SAFE strategy [36, 37]. 
 
Leprosy is caused by the bacteria Mycobacterium leprae, and is mainly spread through the air 
in droplets from infected individuals. The incubation period can be long, and the disease 
typically evolves in two stages; loss of sensation and muscle weakness, and thereafter 
permanent loss of vision and shortening of digits. The disease is targeted for global 
elimination by 2020 [1]. In 2013, more than 215,000 new leprosy cases were detected 
worldwide, and more than half of the cases are found in India alone. WHO focuses on early 
detection and antibiotic combination therapy in endemic countries, and the number of 
reported cases is declining steadily [1]. However, stigma caused by the disease may severely 
affect mental health, and can represent a major obstacle to early detection and treatment [38].  
 
                                                     
3 Corneal damage due to scraping by the lashes of inverted eyelids. 
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Guinea worm disease, or dracunculiasis, is caused by Dracunculus medinensis, also known 
as Guinea worm. Humans get infected through unclean drinking water containing water fleas 
infected with guinea worm larvae. The female larvae can grow to meter-long worms, 
emerging from the skin through painful blisters about a year after infection [39]. The disease 
is the only NTD targeted for eradication4 by 2020. There is no effective medicine or vaccine 
for the disease, and access to improved drinking water and promotion of healthy behaviour 
change are essential public health interventions. In the 1980s, Guinea worm disease was 
endemic in 20 countries with over 3 million cases every year, while in 2013, only 148 cases 
were found in five countries (Sudan, South Sudan, Chad, Ethiopia and Mali) [40]. During the 
first five months of 2015, only five cases were reported [41]. 
                                                     
4 Eradication is defined by WHO as: ”The permanent reduction to zero of the worldwide 
incidence of infection (…), with no risk of reintroduction.” 
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STRENGHTENING CONTROL AND MOVING TOWARDS ELIMINATION 
Current reports indicate a large variation in treatment coverage across the various NTDs 
targeted through MDA; schistosomiasis having the poorest global coverage with only 14% of 
those in need receiving treatment [1]. Onchocerciasis control programmes, on the other hand, 
have been successful in demonstrating the value of sustained, high treatment coverage in 
disease control, and potentially elimination [28]. In certain previously high-endemic areas, 
loss of eyesight has been completely eliminated as a cause of debilitating dysfunction [1]. 
 
Among the suggested success factors of sustained and high treatment coverage of 
onchocerciasis control programmes, the so-called community-directed treatment has been 
brought forward, and especially its local ownership, drug distribution on the premises of local 
communities, and limited or no financial incentives [42]. Although the successes of 
onchocerciasis control seem obvious best practices also for other NTD control programmes, 
the systematic use of lessons learned and scientific knowledge generation still lags behind as 
the control of NTDs needs to readjust if it is to achieve the 2020 WHO targets [43]. 
 
Health education for behaviour change 
Appropriate health education is crucial for the success of most public health interventions, 
and has been shown to be essential also in global health programmes, although there is little 
evidence of the optimal format or frequency of such education [44]. A cluster-randomized 
trial in Uganda of behavioural change communication (BCC) for the use of insecticide-treated 
bed nets for malaria prevention found that additional health education beyond the standard 
programmatic BCC was not cost-effective [44]. Other studies suggest that the effect of the 
health intervention may increase with intensified health education, although cost-effectiveness 
analyses of these results are not clear [38, 45-48]. Few studies, and to our knowledge, only 
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one randomised controlled trial (RCT), have evaluated the effect and best practices for 
behaviour change in NTD control programmes. One RCT did not find any significant 
difference in health behaviour between groups participating and not in a short-term health 
education programme on schistosomiasis [49]. 
 
Ensuring treatment compliance 
Treatment coverage surveys suggest that one of the main factors of successful MDA 
programmes is to appropriately address potential misconceptions of treatment, as well as the 
acceptance of often ill-tasting drugs with unwanted, mostly mild side effects [50-53]. Some 
have found that local communities may for example perceive western medicine as 
“witchcraft”, designed to make its members impotent or infertile [54]. Moreover, fear of side 
effects may prevent appropriate dosage, which in turn may lead to unwanted drug resistance 
[55, 56]. Also, when the drugs do not produce the same side effects as during initial treatment 
rounds, due to reduced parasite-associated symptoms, some may be led to believe the drugs 
are no longer efficient. No controlled, quantitative trials have been conducted to inform NTD 
control programmes of the most cost-efficient ways to ensure adherence to treatment. 
 
Addressing the socio-political context 
Some studies highlight the potential challenges of the wording of diseases and treatment in 
various languages, whereas others suggest that the gender of the drug distributors may affect 
treatment coverage results of MDA programmes [55]. Furthermore, NTD control programmes 
are required to take into account the socio-political context, not only in terms of safety and 
programme feasibility, but equally important, in terms of the local communities’ trust towards 
drug distributors and programme evaluators [57]. 
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In line with the success of onchocerciasis control programmes, studies indicate that the 
involvement of local stakeholders and community leaders is essential to ensure community 
buy-in and treatment coverage [58, 59]. One review found that educating traditional healers 
could improve the capacities of the local community and their support of health programmes 
[60, 61]. 
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DISCUSSION 
The community-directed treatment of onchocerciasis (APOC) stands as an example of how 
the understanding of local social and cultural aspects may strengthen the control of infectious 
diseases. While the quantitative evidence of the effect of strategies such as health education to 
improve healthy behaviour and treatment adherence is scarce, qualitative data indicate that 
these efforts are worthwhile. Addressing the socio-political context in communities affected 
by NTDs is essential to the development of successful and efficient treatment programmes. 
 
In order to ensure sustainable and cost-efficient treatment programmes, the control of NTDs 
needs to integrate social sciences’ knowledge base of how social, cultural and physical 
environments may affect health behaviour [62, 63]. Despite successes such as APOC, social 
sciences, including medical anthropology, have not been widely integrated into the 
development of policies and decision-making of NTD control programmes. This might in part 
be due to the current drive for quantitative evidence of health effects of a given 
implementation or strategy, typical for evidence-based medical sciences [62]. 
 
Understanding the implications of social and cultural behaviour was essential to combat the 
recent Ebola epidemic in West Africa. A large number of individuals were infected through 
traditional burial rituals, which commonly involved physical contact with the deceased, and 
thereby contact with highly infectious material. Indeed, a study in Guinea showed that 85 
confirmed Ebola cases could be linked to one single funeral ceremony in December 2014 
[64]. As a consequence, mourning relatives were encouraged to abstain from traditional burial 
rituals, and in Sierra Leone, a campaign called “Safe Burials Save Lives” allowed 
professional burial teams to take care of the burial routines in a safe manner, while 
incorporating some ceremonial traditions where possible [65, 66]. However, the global health 
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community has been criticised for not addressing the essential social scientific aspects soon 
enough in the outbreak response, and that the development of appropriate health messages for 
the affected communities could have been more effective, and more lives saved, if medical 
anthropology had been integrated at an earlier point in time [67]. 
 
In the treatment of tuberculosis, one study investigated the effect of monthly vouchers of 
approximately $15 which could be used in local shops for food. For those who received the 
voucher at least once, treatment success rates were significantly improved [68]. Other results 
suggest that food vouchers do not have an effect on improved outcomes [69]. The evidence is 
still limited, and challenges still remain with regard to scaling such interventions. 
 
Several global health programmes have recently taken advantage of the rapid development of 
and access to technology, including the use of mobile phones and text message reminders to 
increase treatment adherence among targeted individuals [70, 71]. Even health workers’ 
performance may be improved through text messages [72]. Recently, a study in Burkina Faso 
has been put in place to evaluate the effect of mass media interventions on health benefits 
through an RCT design [73]. The intervention population in this study is exposed to radio 
spots for 30 months, at least 10 times a day (so-called saturation approach), designed to 
stimulate various healthy behaviour changes, such as seeking treatment at clinics for fever and 
diarrhoea or saving money for an emergency during pregnancy. This intervention is being 
compared to control populations without exposure to the same radio spots. The midterm 
results, although not yet published in peer-reviewed literature, have so far shown significant 
improvements, especially in behaviours like seeking treatment for diarrhoea and taking oral 
rehydration therapy [38]. The long-term effects of various mass media interventions and their 
cost-effectiveness; however, have yet to be determined [45].  
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There still remains an untapped potential to leverage social sciences for BCC, health 
messaging and education campaigns in order to improving the effects of MDA programmes 
[74]. Studies suggest that even though MDA coverage may initially be high, this may not 
consistently lead to long-term treatment adherence [53, 56]. This could be due to fear of side 
effects, distrust of modern medicine, lack of perceived need for treatment, or simply omitting 
to take the distributed medication [59]. To counter these unwanted effects, there is a need for 
people at risk to be adequately sensitised. Several studies suggest that the distribution of pre-
MDA educational messages can improve compliance, such as through drug distributors who 
can help alleviate fear and prepare the individuals in need of treatment [53, 56, 59]. 
 
Even though funding for NTDs has increased over the past years, social sciences are still a 
neglected aspect of NTD control programmes, and few studies have evaluated the use of 
social sciences to strengthen NTD control programmes [75, 76]. As funding may be 
increasing, there is a need for increased interdisciplinary cooperation in order to reach the set 
2020 targets [77]. The social aspects of NTD control are complex, and may be challenging to 
study through the use of quantitative research methods. However, studies have indicated that 
making use of social sciences when planning control programmes for NTDs can be highly 
cost-effective, and lessons learned from other infectious disease control should be integrated 
into current and future NTD control and elimination programmes [50]. 
 
In conclusion, social sciences, including medical anthropology, have for a long time been a 
neglected aspect of NTD control programmes. The results of leveraging social interventions 
to control emerging infectious diseases should lend inspiration to the fight against NTDs. 
There is a need for creative, yet robust study designs to address the challenges of 
quantitatively measuring relevant aspects of social sciences in a meaningful way. Qualitative 
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studies of other global health challenges indicate that social sciences do have an important 
role to play, and medical, public health and social scientists will need to find ways of working 
together in order to successfully combat NTDs. 
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